Research of irinotecan stability in different methods of active loading into liposomes
Irinotecan active encapsulation mechanisms into liposomes according “pH gradient” and “ammonium gradient” technologies were considered.
Aim. Research of Irinotecan stability at typical for each “chemical gradient” technology pH values, and estimation of the impurities content correspondence with Draft quality control methods on " Related impurities” index, using Irinotecan conversion mechanism data.
Methods. HPLC method was used for research, using Shimadzu LC-20 appliance, according to the USP impurities control method for semisynthetic product.
Results. Impurity formation dynamics, similar to Irinotecane E lactone ring destruction product, was studied in 3 stages: at pH values 1.9, 5.0, and 5.5. Impurities formation wasn’t observed at pH 1.9, and Irinotecan was stable during observation period – within 12 hours. At pH 5.0, Irinotecan was stable during 12 hours, while impurities formation in quantity over specifications for the finished product was not observed. At pH 5.5, which is specific for the “ammonium gradient” technology, impurities formation was observed in one hour, which is more than 3 times exceeds permissible norms for impurities content in Liposomal Irinotecan finished dosage form.
Conclusion. It has been found, that in terms of active compound stability, “pH gradient” technology is preferred compared to the “ammonium gradient” technology. After using “pH gradient” technology, “Related impurities” index corresponded to the Draft quality control methods. The obtained data were used for Irinotecan liposomal dosage form development for the further preclinical and clinical study
Full Text:PDF (Русский)
Prakash, O., Kumar, A., Kumar, P., Ajeet, A. (2013). Anticancer Potential of Plants and Natural Products: A Review. American Journal of Pharmacological Sciences, 1 (6), 104–115. doi: 10.12691/ajps-1-6-1
Xu, Y. (2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of Oncology, 13 (12), 1841–1851. doi: 10.1093/annonc/mdf337
Ramsay, E. C., Anantha, M., Zastre, J., Meijs, M., Zonderhuis, J., Strutt, D. et. al. (2008). Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. Clinical Cancer Research, 14 (4), 1208–1217. doi: 10.1158/1078-0432.ccr-07-0780
West-Ward Pharmaceuticals Corp. Irinotecan prescribing information (2016). Drugs.com. Available at: https://www.drugs.com/pro/irinotecan.html
Fassberg, J., Stella, V. J. (1992). A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues. Journal of Pharmaceutical Sciences, 81 (7), 676–684. doi: 10.1002/jps.2600810718
Li, W. Y., Koda, R. (2002). Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm, 59 (6), 539–544.
Tardi, P. G., Dos Santos, N., Harasym, T. O., Johnstone, S. A., Zisman, N., Tsang, A. W. et. al. (2009). Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Molecular Cancer Therapeutics, 8 (8), 2266–2275. doi: 10.1158/1535-7163.mct-09-0243
Ramsay, E. (2008). A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. European Journal of Pharmaceutics and Biopharmaceutics, 68 (3), 607–617. doi: 10.1016/j.ejpb.2007.08.011
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., Pedraz, J. L. (2012). Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clinical and Translational Oncology, 14 (2), 83–93. doi: 10.1007/s12094-012-0766-6
Messerer, C. L. (2004). Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer. Clinical Cancer Research, 10 (19), 6638–6649. doi: 10.1158/1078-0432.ccr-04-0221
GOST Style Citations
1. Prakash, O. Anticancer Potential of Plants and Natural Products: A Review [Text] / O. Prakash, A. Kumar, P. Kumar, A. Ajeet // American Journal of Pharmacological Sciences. – 2013. – Vol. 1, Issue 6. – P. 104–115. doi: 10.12691/ajps-1-6-1
2. Xu, Y. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity [Text] / Y. Xu // Annals of Oncology. – 2002. – Vol. 13, Issue 12. – P. 1841–1851. doi: 10.1093/annonc/mdf337
3. Ramsay, E. C. Irinophore C: A liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors [Text] / E. C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt et. al. / Clinical Cancer Research. – 2008. – Vol. 14, Issue 4. – P. 1208–1217. doi: 10.1158/1078-0432.ccr-07-0780
4. West-Ward Pharmaceuticals Corp. Irinotecan prescribing information [Electronic resource]. – Drugs.com. – 2016. – Available at: https://www.drugs.com/pro/irinotecan.html
5. Fassberg, J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues [Text] / J. Fassberg, V. J. Stella // Journal of Pharmaceutical Sciences. – 1992. – Vol. 81, Issue 7. – P. 676–684. doi: 10.1002/jps.2600810718
6. Li, W. Y. Stability of irinotecan hydrochloride in aqueous solutions [Text] / W. Y. Li., R. Koda // Am J Health-Syst Pharm. – 2002. – Vol. 59, Issue 6. – P. 539–544.
7. Tardi, P. G. Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitroand in vivo [Text] / P. G. Tardi, N. Dos Santos, T. O. Harasym, S. A. Johnstone, N. Zisman, A. W. Tsang et. al. // Molecular Cancer Therapeutics. – 2009. – Vol. 8, Issue 8. – P. 2266–2275. doi: 10.1158/1535-7163.mct-09-0243
8. Ramsay, E. A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention [Text] / E. Ramsay // European Journal of Pharmaceutics and Biopharmaceutics. – 2008. – Vol. 68, Issue 3. – P. 607–617. doi: 10.1016/j.ejpb.2007.08.011
9. Egusquiaguirre, S. P. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research [Text] / S. P. Egusquiaguirre, M. Igartua, R. M. Hernández, J. L. Pedraz // Clinical and Translational Oncology. – 2012. – Vol. 14, Issue 2. – P. 83–93. doi: 10.1007/s12094-012-0766-6
10. Messerer, C. L. Liposomal Irinotecan. Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer [Text] / C. L. Messerer // Clinical Cancer Research. – 2004. – Vol. 10, Issue 19. – P. 6638–6649. doi: 10.1158/1078-0432.ccr-04-0221
Copyright (c) 2016 Александр Викторович Стадниченко, Юрий Михайлович Краснопольский, Виталий Иванович Швец, Татьяна Григорьевна Ярных
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2519-4852 (Online), ISSN 2519-4844 (Print)